The term epigenetics refers to the study of alterations in genes that are not facilitated by any change in their DNA sequence. The epigenetic condition of a cell is affected by both developmental and environmental factors, including nutrition, toxins, infection and drug abuse. The Europe epigenomics market is anticipated to grow with a CAGR of 16.78% over the forecast years of 2018-2026.

EUROPE EPIGENOMICS MARKET FORECAST 2018-2026

Europe Epigenomics Market by Product (Reagents, Kits, Instruments, Enzymes, Services) by Technology (Dna Methylation, Histone Methylation & Acetylation, Microrna Modification) by Application (Oncology, Non-oncology) by Application Area (Diagnosis, Drug Discovery, Therapy Optimization, Prognosis) by Segment (Epigenetic Diagnosis(Cancer, Neuro, Inflammatory & Autoimmune Disease, R&d, Personalized Medicine, Neurological Disorders, Cvd, Others), Epigenetic Therapies(Biomarkers, Noncoding Rnas, Mirnas, Chromatin Remodeling)) by Geography.

Request free sample

The term epigenetics refers to the study of alterations in genes that are not facilitated by any change in their DNA sequence. The epigenetic condition of a cell is affected by both developmental and environmental factors, including nutrition, toxins, infection and drug abuse. The Europe epigenomics market is anticipated to grow with a CAGR of 16.78% over the forecast years of 2018-2026.

France, Germany, UK, Italy, Spain and the rest of Europe are the geographic analyzed for the Europe epigenomics market. In the year 2017, France dominated this region. Although the oncology application is well established, the non-oncology application too is gaining ground in this market. These applications include symptomatic relief and prolonged patient life for degenerative disorders such as Parkinson’s, Huntington’s, and Alzheimer’s.

Eminent market companies engaged in the epigenomic market include Glaxosmithkline, Abbott Laboratories, Orchid Chemicals & Pharmaceuticals Limited, Novartis Pharma Ag, Agilent Technologies, Celgene Corp, Naturewise Biotech & Medicals Corp, Bayer Ag, Illumina Inc, Affymetrix, Roche Holding Ag, Johnson & Johnson, Rubicon Genomics, and others.

 

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • ASIA PACIFIC IS ANTICIPATED TO BE THE MOST DYNAMIC REGIONAL MARKET
        • REAGENTS FORMS A MAJOR PART OF EPIGENOMIC MARKET BY PRODUCT
        • EPIGENETICS DIAGNOSIS IS A MAJOR PART OF EPIGENOMIC MARKET, AND PERSONALIZED MEDICINES IS SHOWING A DYNAMIC GROWTH
        • ONCOLOGY IS THE PRIMARY APPLICATION WHILE NON-ONCOLOGY IS SHOWING A BETTER GROWTH
    1. MARKET DYNAMICS
      • MARKET DEFINITION & SCOPE
      • MARKET DRIVERS
        • ADVANCEMENT IN THE PREVALENCE OF CANCER AND OTHER CHRONIC DISEASES
        • RISE IN THE AGEING POPULATION
        • DECLINE IN THE SEQUENCING COSTS AND TIME
        • ESCALATION IN FUNDING FOR RESEARCH & DEVELOPMENT
        • NEED FOR BETTER CANCER THERAPIES
        • GROWTH IN PERSONALIZED MEDICINE
        • INCREASING IMPORTANCE OF EPIGENETIC TECHNOLOGY
      • MARKET RESTRAINTS
        • INEFFICIENCY IN IDENTIFICATION AND VALIDATION OF BIOMARKER
        • PRESENCE OF COMPLEX REGULATORY FRAMEWORK
        • LACK OF REIMBURSEMENT PROVISION IN INSURANCE FOR EPIGENOMIC
      • MARKET OPPORTUNITIES
        • INCREASING AWARENESS ABOUT EPIGENOMIC
        • ADVANCEMENT OF POTENTIAL IN EMERGING MARKETS
        • EXPANDING APPLICATIONS OF EPIGENETICS IN PERSONALIZED MEDICINE AND TARGETED THERAPY
        • USE OF EPIGENOMIC IN NON-ONCOLOGY APPLICATIONS
      • MARKET CHALLENGES
        • SCARCITY OF TRAINED PROFESSIONALS
        • HIGH COST OF INSTRUMENTS AND CONSUMABLES
    2. MARKET BY PRODUCT
      • REAGENTS
      • KITS
      • INSTRUMENTS
      • ENZYMES
      • SERVICES
    3. MARKET BY TECHNOLOGY
      • DNA METHYLATION
      • HISTONE METHYLATION & ACETYLATION
      • MICRORNA MODIFICATION
    4. MARKET BY APPLICATION
      • ONCOLOGY
        • DNA METHYLTRANSFERASE INHIBITORS
        • HISTONE DEACETYLASE INHIBITORS
      • NON-ONCOLOGY
    5. MARKET BY APPLICATION AREA
      • DIAGNOSIS
      • DRUG DISCOVERY
      • THERAPY OPTIMIZATION
      • PROGNOSIS
    6. MARKET BY SEGMENT
      • EPIGENETIC DIAGNOSIS
        • CANCER
        • NEURO
          • MENTAL RETARDATION
          • ALZHEIMER’S DISEASE
          • DEPRESSION
          • OTHER
        • CARDIOVASCULAR
          • VASCULAR DISEASE
          • HEART FAILURE
          • OTHERS
        • INFLAMMATORY & AUTOIMMUNE DISEASE
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • LUPUS
          • MULTIPLE SCLEROSIS
          • INFLAMMATORY BOWEL DISEASES
        • R&D
          • DNA METHYLATION IN CANCER DETECTION
          • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
          • MECHANISMS OF EPIGENETIC GENE SILENCING
        • PERSONALIZED MEDICINE
          • CANCER TREATMENT
            • LUNG CANCER
            • SOLID CANCERS
            • GASTRIC CANCER
            • HAEMATOLOGICAL CANCERS
            • OTHERS
          • NEUROLOGICAL DISORDERS
            • MENTAL RETARDATION
            • HUNTINGTON’S DISEASE
            • PARKINSON’S DISEASE
            • ALZHEIMER’S DISEASE
            • DEPRESSION
          • CVD
          • OTHERS
            • RHEUMATOID ARTHRITIS
            • DIABETES
            • MYELODYSPLASTIC SYNDROMES
            • MULTIPLE SCLEROSIS
            • OBESITY
            • INFLAMMATORY BOWEL DISEASES
            • LUPUS
            • OTHER
      • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING
    7. KEY ANALYTICS
      • PORTER’S FIVE FORCE MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF SUPPLIERS
        • BARGAINING POWER OF BUYERS
        • THREAT OF COMPETITIVE RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
    8. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • UNITED KINGDOM
        • FRANCE
        • ITALY
        • SPAIN
        • REST OF EUROPE
    9. COMPANY PROFILES
      • ABBOTT LABORATORIES
      • AFFYMETRIX
      • AGILENT TECHNOLOGIES
      • ASTELLAS PHARMACEUTICALS
      • BAYER AG
      • CELGENE CORP.
      • EPIGENOMICS AG
      • GLAXOSMITHKLINE
      • ILLUMINA INC.
      • JOHNSON & JOHNSON
      • MERCK SHARP & DOHME
      • NOVARTIS PHARMA AG
      • RUBICON GENOMICS
      • ROCHE HOLDING AG

     

     

    LIST OF TABLES

    TABLE 1 EUROPE EPIGENOMIC MARKET, BY COUNTRY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 2 EUROPE EPIGENOMIC MARKET, BY PRODUCT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 3 EUROPE EPIGENOMIC MARKET, BY TECHNOLOGY, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 4 EUROPE EPIGENOMIC MARKET, BY APPLICATION, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 5 EUROPE EPIGENOMIC MARKET, BY APPLICATION AREA, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 6 EUROPE EPIGENOMIC MARKET, BY SEGMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 7 EUROPE EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 8 EUROPE EPIGENETIC DIAGNOSIS MARKET, BY NEURO, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 9 EUROPE EPIGENETIC DIAGNOSIS MARKET, BY CARDIOVASCULAR, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 10 EUROPE EPIGENETIC DIAGNOSIS MARKET, BY INFLAMMATORY & AUTOIMMUNE DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 11 EUROPE EPIGENETIC DIAGNOSIS MARKET, BY R&D, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 12 EUROPE EPIGENOMIC MARKET, BY PERSONALIZED MEDICINE, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 13 EUROPE PERSONALIZED MEDICINE MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

    TABLE 14 EUROPE PERSONALIZED MEDICINE MARKET, BY NEUROLOGICAL DISORDERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 15 EUROPE PERSONALIZED MEDICINE MARKET, BY OTHERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 16 EUROPE EPIGENOMICS MARKET, BY BIOMARKERS, 2018-2026 (IN $ TEN THOUSAND)

    TABLE 17 OPPORTUNITY MATRIX

    TABLE 18 VENDOR LANDSCAPE

    TABLE 19 EUROPE EPIGENOMIC MARKET, BY COUNTRY, 2018-2026 (IN $ TEN THOUSAND)

     

    LIST OF FIGURES

    FIGURE 1 EUROPE EPIGENOMIC MARKET SHARE, BY SEGMENT 2017 & 2026 (%)

    FIGURE 2 EUROPE REVENUE ESTIMATION ($ TEN THOUSAND)

    FIGURE 3 REAGENTS ESTIMATED REVENUE ($TEN THOUSAND)

    FIGURE 4 EPIGENETIC DIAGNOSIS ESTIMATED REVENUE ($ TEN THOUSAND)

    FIGURE 5 PERSONALIZED MEDICINES ESTIMATED REVENUE ($ TEN THOUSAND)

    FIGURE 6 ONCOLOGY REVENUE ESTIMATION ($ TEN THOUSAND)

    FIGURE 7 NON-ONCOLOGY REVENUE ESTIMATION ($ TEN THOUSAND)

    FIGURE 8 EUROPE EPIGENOMIC MARKET, BY REAGENTS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 9 EUROPE EPIGENOMIC MARKET, BY KITS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 10 EUROPE EPIGENOMIC MARKET, BY INSTRUMENTS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 11 EUROPE EPIGENOMIC MARKET, BY ENZYMES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 12 EUROPE EPIGENOMIC MARKET, BY SERVICES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 13 EUROPE EPIGENOMIC MARKET, BY DNA METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 14 EUROPE EPIGENOMIC MARKET, BY HISTONE METHYLATION AND ACETYLATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 15 EUROPE EPIGENOMIC MARKET, BY MICRO-RNA MODIFICATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 16 EUROPE EPIGENOMIC MARKET, BY ONCOLOGY, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 17 EUROPE EPIGENOMIC MARKET, BY DNA METHYLTRANSFERASE INHIBITORS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 18 EUROPE EPIGENOMIC MARKET, BY HISTONE DEACETYLASE INHIBITORS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 19 EUROPE EPIGENOMIC MARKET, BY NON-ONCOLOGY, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 20 EUROPE EPIGENOMIC MARKET, BY DIAGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 21 EUROPE EPIGENOMIC MARKET, BY DRUG DISCOVERY, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 22 EUROPE EPIGENOMIC MARKET, BY THERAPY OPTIMIZATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 23 EUROPE EPIGENOMIC MARKET, BY PROGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 24 EUROPE EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 25 EUROPE EPIGENOMIC MARKET, BY EPIGENETIC DIAGNOSIS-CANCER, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 26 EUROPE EPIGENOMIC MARKET, BY NEURO-MENTAL RETARDATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 29 EUROPE EPIGENOMIC MARKET, BY NEURO- ALZHEIMER’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 30 EUROPE EPIGENOMIC MARKET, BY NEURO- DEPRESSION, 2018-2 026, (IN $ TEN THOUSAND)

    FIGURE 31 EUROPE EPIGENOMIC MARKET, BY NEURO- OTHER, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 32 EUROPE EPIGENOMIC MARKET, BY CARDIOVASCULAR-VASCULAR DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 33 EUROPE EPIGENOMIC MARKET, BY CARDIOVASCULAR- HEART FAILURE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 34 EUROPE EPIGENOMIC MARKET, BY CARDIOVASCULAR- OTHERS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 35 EUROPE EPIGENOMIC MARKET, BY RHEUMATOID ARTHRITIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 36 EUROPE EPIGENOMIC MARKET, BY DIABETES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 37 EUROPE EPIGENOMIC MARKET, BY LUPUS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 38 EUROPE EPIGENOMIC MARKET, BY MULTIPLE SCLEROSIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 39 EUROPE EPIGENOMIC MARKET, BY INFLAMMATORY BOWEL DISEASES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 40 EUROPE EPIGENOMIC MARKET, BY DNA METHYLATION IN CANCER DETECTION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 41 EUROPE EPIGENOMIC MARKET, BY IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 42 EUROPE EPIGENOMIC MARKET, BY MECHANISMS OF EPIGENETIC GENE SILENCING, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 43 EUROPE EPIGENOMIC MARKET, BY CANCER TREATMENT, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 44 EUROPE EPIGENOMIC MARKET, BY LUNG CANCER, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 45 EUROPE EPIGENOMIC MARKET, BY SOLID CANCERS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 46 EUROPE EPIGENOMIC MARKET, BY GASTRIC CANCER, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 47 EUROPE EPIGENOMIC MARKET, BY HEMATOLOGICAL CANCERS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 48 EUROPE EPIGENOMIC MARKET, BY OTHERS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 49 EUROPE EPIGENOMIC MARKET, BY MENTAL RETARDATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 50 EUROPE EPIGENOMIC MARKET, BY HUNTINGTON’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 51 EUROPE EPIGENOMIC MARKET, BY PARKINSON’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 52 EUROPE EPIGENOMIC MARKET, BY ALZHEIMER’S DISEASE, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 53 EUROPE EPIGENOMIC MARKET, BY DEPRESSION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 54 EUROPE EPIGENOMIC MARKET, BY CVD, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 55 EUROPE EPIGENOMIC MARKET, BY RHEUMATOID ARTHRITIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 56 EUROPE EPIGENOMIC MARKET, BY DIABETES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 57 EUROPE EPIGENOMIC MARKET, BY MYELODYSPLASTIC SYNDROMES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 58 EUROPE EPIGENOMIC MARKET, BY MULTIPLE SCLEROSIS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 59 EUROPE EPIGENOMIC MARKET, BY OBESITY, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 60 EUROPE EPIGENOMIC MARKET, BY INFLAMMATORY BOWEL DISEASES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 61 EUROPE EPIGENOMIC MARKET, BY LUPUS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 62 EUROPE EPIGENOMIC MARKET, BY OTHER, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 63 EUROPE EPIGENOMIC MARKET, BY EPIGENETIC THERAPIES, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 64 EUROPE EPIGENOMIC MARKET, BY BIOMARKERS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 65 EUROPE EPIGENOMIC MARKET, BY DNA METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 66 EUROPE EPIGENOMIC MARKET, BY HISTONIC MODIFICATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 67 EUROPE EPIGENOMIC MARKET, BY HISTONE METHYLATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 68 EUROPE EPIGENOMIC MARKET, BY HISTONE ACETYLATION, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 69 EUROPE EPIGENOMIC MARKET, BY NONCODING RNAS, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 70 EUROPE EPIGENOMIC MARKET, BY MIRNAS, 20 18-2026, (IN $ TEN THOUSAND)

    FIGURE 71 EUROPE EPIGENOMIC MARKET, BY CHROMATIN REMODELING, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 72 PORTER’S FIVE FORCE MODEL

    FIGURE 73 EUROPE EPIGENOMIC MARKET, COUNTRY OUTLOOK, 2018-2026, (IN $ TEN THOUSAND)

    FIGURE 74 GERMANY EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    FIGURE 75 UNITED KINGDOM EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    FIGURE 76 FRANCE EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    FIGURE 77 ITALY EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    FIGURE 78 SPAIN EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    FIGURE 79 REST OF EUROPE EPIGENOMIC MARKET, 2018-2026 (IN $ TEN THOUSAND)

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • GERMANY
        • UNITED KINGDOM
        • FRANCE
        • ITALY
        • SPAIN
        • REST OF EUROPE
    1. MARKET BY PRODUCT
      • REAGENTS
      • KITS
      • INSTRUMENTS
      • ENZYMES
      • SERVICES
    2. MARKET BY TECHNOLOGY
      • DNA METHYLATION
      • HISTONE METHYLATION & ACETYLATION
      • MICRORNA MODIFICATION
    3. MARKET BY APPLICATION
      • ONCOLOGY
        • DNA METHYLTRANSFERASE INHIBITORS
        • HISTONE DEACETYLASE INHIBITORS
      • NON-ONCOLOGY
    4. MARKET BY APPLICATION AREA
      • DIAGNOSIS
      • DRUG DISCOVERY
      • THERAPY OPTIMIZATION
      • PROGNOSIS
    5. MARKET BY SEGMENT
      • EPIGENETIC DIAGNOSIS
        • CANCER
        • NEURO
          • MENTAL RETARDATION
          • ALZHEIMER’S DISEASE
          • DEPRESSION
          • OTHER
        • CARDIOVASCULAR
          • VASCULAR DISEASE
          • HEART FAILURE
          • OTHERS
        • INFLAMMATORY & AUTOIMMUNE DISEASE
          • RHEUMATOID ARTHRITIS
          • DIABETES
          • LUPUS
          • MULTIPLE SCLEROSIS
          • INFLAMMATORY BOWEL DISEASES
        • R&D
          • DNA METHYLATION IN CANCER DETECTION
          • IDENTIFICATION OF EPIGENETIC BIOMARKERS FOR DIAGNOSIS AND PREDICTION
          • MECHANISMS OF EPIGENETIC GENE SILENCING
        • PERSONALIZED MEDICINE
          • CANCER TREATMENT
            • LUNG CANCER
            • SOLID CANCERS
            • GASTRIC CANCER
            • HAEMATOLOGICAL CANCERS
            • OTHERS
          • NEUROLOGICAL DISORDERS
            • MENTAL RETARDATION
            • HUNTINGTON’S DISEASE
            • PARKINSON’S DISEASE
            • ALZHEIMER’S DISEASE
            • DEPRESSION
          • CVD
          • OTHERS
            • RHEUMATOID ARTHRITIS
            • DIABETES
            • MYELODYSPLASTIC SYNDROMES
            • MULTIPLE SCLEROSIS
            • OBESITY
            • INFLAMMATORY BOWEL DISEASES
            • LUPUS
            • OTHER
      • EPIGENETIC THERAPIES
        • BIOMARKERS
          • DNA METHYLATION FOR CANCER DETECTION
          • HISTONIC MODIFICATION AS BIOMARKER IN CANCER DETECTION
            • HISTONE METHYLATION
            • HISTONE ACETYLATION
          • NONCODING RNAS
          • MIRNAS
          • CHROMATIN REMODELING

     

    To request a free sample copy of this report, please complete the form below :
    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type